NewBridge enters accord to distribute Kyowa Kirin products across MENA region

The Kyowa Kirin International (KKI) unit of Japanese drugmaker Kyowa Kirin (TYO: 4151) has entered a collaboration with NewBridge Pharmaceuticals.

The agreement will see NewBridge Pharmaceuticals act as a distributor in four countries across the Middle East and North Africa (MENA) region for KKI’s current rare disease portfolio. No financial terms of the collaboration were disclosed.

This agreement with NewBridge will bring access to medicines within a population of 100 million across Algeria, Iraq, Libya and Jordan supporting Kyowa Kirin’s International’s commitment to geographical expansion to meet the needs of more patients across the international region.